登录新浪财经APP 搜索【信披】查看更多考评等级 格隆汇8月3日丨九洲药业(603456.SH)公告，浙江九洲药业股份有限公司(以下简称"公司")将于2025年8 月6日在上海证券交易所网站(www.sse.com.cn)披露公司2025年半年度报告。为便于广大投资者更全面、 深入地了解公司业绩和经营情况，公司计划于2025年8月11日(星期一)15:00-16:00召开2025年半年度业 绩说明会。公司将针对2025年半年度业绩、经营情况与投资者进行充分交流，在信息披露允许的范围内 就投资者普遍关注的公司经营业绩、战略规划、财务状况、利润分配等问题进行回答，欢迎广大投资者 积极参与。 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-045 浙江九洲药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 投资者可于 2025 年 8 月 4 日（星期一）至 8 月 8 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （603456@jiuzhoupharma.com）进行提问，公司将在信息披露允许的范围内对投 资者普遍关注的问题进行回答。 一、说明会类型 浙江九洲药业股份有限公司（以下简称"公司"）将于 2025 年 8 月 6 日在上 海证券交易所网站（www.sse.com.cn）披露公司 2025 年半年度报告。为便于广 大投资者更全面、深入地了解公司业绩和经营情况，公司计划于 2025 年 8 月 11 日（星期一）15:00-16:00 召开 2025 年半年度业绩说明会。公司将针对 2025 年 半年度业绩、经营情况与投资者进行充分交流，在信息披露允许的范围内就投资 者普遍关注的公司经营业绩、战略规划、财务状况、利润分配等问题进行回答， 欢迎广大投资者积极参与。 二、说明会召开的时间、地点及方式 1、会议召开时间： ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 13.30 | -6.60% | 97.13万 | 13.47 乙 | | 688710 | 益诺思 | 42.93 | -4.34% | 2.77万 | 1.21亿 | | 300725 | 药石科技 | 47.25 | -4.08% | 22.57万 | 10.92亿 | | 603456 | 九州药业 | 18.32 | -3.48% | 63.91万 | 11.90亿 | | 603259 | 药明康德 | 93.00 | -3.40% | 89.33万 | 83.98亿 | | 300759 | 康龙化成 | 30.10 | -3.22% | 61.22万 | 18.70亿 | | 688202 | 美迪西 | 61.60 | -2.84% | 7.28万 | 4.55 Z | | 002173 | 创新医疗 | 14.92 | -2.74% | 81.94万 | 12.53亿 | | 002821 | 司 ...

Core Viewpoint - The company has approved the use of idle raised funds for cash management, amounting to 785 million RMB, to enhance fund efficiency while ensuring the safety and liquidity of investments [1][7][12]. Summary by Sections Cash Management Overview - The cash management is aimed at improving fund efficiency and ensuring the safety of raised funds while not affecting the ongoing investment projects [2][12]. - The cash management products include bank certificates of deposit with a management period of 3, 6, and 12 months [1][7]. Cash Management Amount and Source - The total amount for cash management is 785 million RMB [4][7]. - The funds are sourced from idle raised funds from the company's non-public offerings in 2020 and 2022 [4][6]. Previous Cash Management Activities - The company previously used 21 million RMB of idle funds for cash management, which was redeemed with the principal and earnings returned to the special account for raised funds [2][5]. Approval Process - The cash management proposal was approved in the board meeting held on December 13, 2024, allowing the company to use up to 1.2 billion RMB for cash management under specific conditions [1][9]. Cash Management Product Details - The cash management products are required to be of high safety and liquidity, and the company ensures that these do not alter the intended use of raised funds [7][12]. - The income generated from cash management will belong to the company and will be returned to the special account upon maturity [8][12]. Impact on Company Operations - The use of idle raised funds for cash management will not affect the company's daily operations or the normal implementation of investment projects, aiming to enhance returns for shareholders [12].

Core Viewpoint - The company, Zhejiang Jiuzhou Pharmaceutical Co., Ltd., has announced the establishment of special settlement accounts for cash management of idle raised funds, amounting to 785 million RMB, to enhance the efficiency of fund utilization and ensure the safety of the funds [1][9]. Group 1: Cash Management Overview - The cash management is entrusted to Industrial and Commercial Bank of China and Agricultural Bank of China [1]. - The cash management products include bank certificates of deposit with terms of 3 months, 6 months, and 12 months [1]. - The board of directors approved the use of up to 1.2 billion RMB of idle raised funds for cash management, ensuring it does not affect the construction and use of investment projects [1][9]. Group 2: Account Establishment - The company has opened sub-accounts for cash management at Agricultural Bank of China branches in Taizhou and Changshu [2]. - These accounts will be exclusively used for cash management of idle raised funds and will not be used for other purposes [4]. Group 3: Previous Cash Management Activities - Previously, the company used 21 million RMB of idle funds for cash management, which was redeemed by July 22, 2025, returning the principal and earnings to the special account [4]. Group 4: Purpose and Benefits of Cash Management - The purpose of cash management is to enhance fund efficiency while ensuring the safety of the raised funds and not impacting ongoing investment projects [5][10]. - The income generated from cash management will belong to the company and will be returned to the special account upon maturity [9]. Group 5: Regulatory Compliance - The cash management activities comply with relevant regulations from the China Securities Regulatory Commission and the Shanghai Stock Exchange [4][10]. - The company has received consent from its sponsor for the cash management activities [10].

Market Overview - The indices continued to rise collectively, with a significant drop in the morning followed by a recovery in sentiment in the afternoon [3] - The Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index closed up by 0.33%, 0.64%, and 1.86% respectively, with over 3,000 stocks declining and more than 2,200 stocks rising [4] Optimizing Fertility - The "Implementation Plan for Childcare Subsidy System" was officially launched, providing annual subsidies of 3,600 yuan per child for children under three years old starting January 1, 2025 [8] - The fertility optimization sector saw a collective high opening but ended with a "high open low close" trend, with the sector rising by only 0.18% after an initial surge [9][10] - Stocks like Beiyinmei and Aiyingshi opened strongly but fell significantly, while stocks in the dairy sector also experienced a similar pattern [10] Yajiang Hydropower Station - The Yajiang Hydropower Station saw a rebound in the afternoon, with stocks like Xining Special Steel and Tibet Tianlu hitting the daily limit [15] - The Yajiang Hydropower concept stocks rose over 2% by the end of the day, indicating a recovery in investor interest [14] Stablecoin Sector - The stablecoin concept stocks experienced a partial rebound, with companies like Hengbao Co. and Sifang Jichuang showing strong performance [19] - The sector had been quiet for about two weeks but is now looking for a significant catalyst to revive interest [21] Guotou Intelligent - Guotou Intelligent saw a significant rise, closing up over 18.5%, attributed to news regarding a special action by the Internet Information Office [25] - The company is reportedly working on AI fraud prevention services, with a potential market space exceeding 120 billion yuan if it covers 1 billion smartphone users [28]

证券代码：603456 证券简称：九洲药业 公告编号：2025-044 浙江九洲药业股份有限公司 关于开立募集资金现金管理产品专用结算账户 及使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理受托方：中国工商银行股份有限公司台州椒江支行（以下简称 "工商银行台州椒江支行"）、中国农业银行股份有限公司台州椒江支行（以下 简称"农业银行台州椒江支行"）、中国农业银行股份有限公司常熟经济开发区 支行（以下简称"农业银行常熟经济开发区支行"）； 履行的审议程序：浙江九洲药业股份有限公司（以下简称"公司"、"九 洲药业"）于2024年12月13日召开的第八届董事会第十一次会议、第八届监事会 第七次会议，审议通过了《关于使用闲置募集资金进行现金管理的议案》，同意 公司及子公司在保障资金安全及确保不影响募集资金投资项目建设和使用计划 的前提下，使用不超过人民币12亿元的闲置募集资金适时购买安全性高、流动性 好的投资产品（包括但不限于结构性存款、定期存款、大额存单、通知存款、收 益 ...

| 688120 | 华海清 | 5 | 1.08 | 4.02 | 5.15 | | --- | --- | --- | --- | --- | --- | | | 科 | | | | | | 300203 | 聚光科 | 6 | 0.99 | 4.90 | 6.41 | | | 技 | | | | | | 688503 | 聚和材 | 5 | 0.98 | 5.57 | 9.57 | | | 料 | | | | | | 600730 | 中国高 | 5 | 0.95 | 7.96 | 16.52 | | | 科 | | | | | | 300870 | 欧陆通 | 5 | 0.90 | 3.85 | 3.84 | | 600038 | 中直股 | 5 | 0.85 | 4.87 | 1.76 | | | 份 | | | | | | 002637 | 赞宇科 | 5 | 0.84 | 5.61 | 7.78 | | | 技 | | | | | | | 申菱环 | | | | | | 301018 | 境 | 5 | 0.80 | 4.91 | 9.67 | | 000708 | 中信特 | 5 | 0.75 ...

医药生物行业今日上涨2.06%，全天主力资金净流入29.96亿元，该行业所属的个股共474只，今日上涨 的有341只，涨停的有11只；下跌的有128只，跌停的有1只。以资金流向数据进行统计，该行业资金净 流入的个股有258只，其中，净流入资金超亿元的有10只，净流入资金居首的是众生药业，今日净流入 资金3.03亿元，紧随其后的是智飞生物、九洲药业，净流入资金分别为2.56亿元、2.50亿元。医药生物 行业资金净流出个股中，资金净流出超亿元的有7只，净流出资金居前的有恒瑞医药、塞力医疗、药明 康德，净流出资金分别为3.52亿元、1.87亿元、1.73亿元。（数据宝） 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002317 | 众生药业 | 9.98 | 15.34 | 30259.16 | | 300122 | 智飞生物 | 6.50 | 9.19 | 25584.13 | | 603456 | 九洲药业 | 10.01 | 12.54 | 24987.61 | | 3 ...

今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | CRO概念 | 4.00 | 猪肉 | -1.35 | | 重组蛋白 | 2.90 | 养鸡 | -1.12 | | 创新药 | 2.79 | 草甘膦 | -1.10 | | 减肥药 | 2.76 | 粮食概念 | -1.00 | | F5G概念 | 2.43 | 芬太尼 | -0.88 | | 细胞免疫治疗 | 2.42 | PEEK材料 | -0.85 | | 仿制药一致性评价 | 2.30 | 预制菜 | -0.85 | | 共封装光学(CPO) | 2.23 | 生态农业 | -0.78 | | 特钢概念 | 2.08 | C2M概念 | -0.78 | | 先进封装 | 1.91 | 人造肉 | -0.76 | 截至7月29日收盘，仿制药一致性评价概念上涨2.30%，位居概念板块涨幅第7，板块内，104股上涨， 亚太药业、九洲药业、辰欣药业等涨停，南新制药、苑东生物、海特生物等涨幅居前，分别上涨 17.01%、15.45%、15.28%。跌幅居前的有昂 ...